anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Midazolam
Trial phase: Not Applicable
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.

oral midazolam: administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
Eligibility criteria:
Inclusion Criteria:

healthy children (ASA 1), uncooperative (Frankl 1-210), that needs at least two similar dental treatments.

Exclusion Criteria:

enlarged tonsils (Brodsky's grading scale11 +3 = 50-75% airway obstruction, and +4 = >75% airway obstruction), upper respiratory tract infection or nasal discharge.
Intervention: Midazolam
Trial phase: Not Applicable
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.

nasal midazolam: administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
Eligibility criteria:
Inclusion Criteria:

healthy children (ASA 1), uncooperative (Frankl 1-210), that needs at least two similar dental treatments.

Exclusion Criteria:

enlarged tonsils (Brodsky's grading scale11 +3 = 50-75% airway obstruction, and +4 = >75% airway obstruction), upper respiratory tract infection or nasal discharge.
Intervention: Fluciclovine (18F)
Trial phase: Phase 3
ATC code: V09IX12
SMILES: N[C@]1(C(=O)O)C[C@@H]([18F])C1
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 213
Group description: Single intravenous administration of 18F-fluciclovine PET CT.
Eligibility criteria:
Inclusion Criteria:

History of histologically confirmed adenocarcinoma of the prostate post curative-intent local treatment (radical prostatectomy, local radiotherapy, brachytherapy).
Suspicion of recurrent prostate carcinoma after previous presumed definitive therapy for organ confined disease defined as :
Post prostatectomy: Detectable or rising PSA level that is >0.2 ng/mL with a second confirmatory level of >0.2 ng/mL
Post non-prostatectomy: PSA rise ≥ 2ng/mL over nadir
Negative or equivocal findings on standard-of-care imaging for restaging of disease in the previous 60 days consisting of: Whole-body 99mTc bone scintigraphy or NaF PET-CT; and either CT or MRI of the pelvis (or the abdomen and pelvis).
Being considered for salvage therapy
Any non-surgical local treatment such as previous cryotherapy, external beam radiation, or HiFU (Ultrasound) must have occurred at least 1 year in the past.
Previous brachytherapy treatment will have occurred at least 2 years in the past
Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

Ongoing treatment with any systemic therapy intended for the treatment of prostate cancer (e.g., antiandrogen or LHRH agonist or antagonist)
Androgen deprivation therapy (ADT) in the past 3 months
History of bilateral orchidectomy
Inability to tolerate 18F-fluciclovine PET/CT
Intervention: Novolog mix 70/30
Trial phase: Phase 4
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 38
Group description: Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.

Insulin, Asp(B28)-: This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
Eligibility criteria:
Inclusion Criteria:

Diagnosis of Type 1 diabetes (for at least a year)
On multiple daily insulin injections, including basal long-acting insulin and rapid-acting insulin before each meal.
HbA1c < 75 mmol/mol (9.0%)
Participant and/or parent/legal guardian willing and able to give informed consent for participation in the study.
Family have a freezer in which to safely store the test meals.
In the Investigator's opinion, is able and willing to comply with all trial requirements.

Exclusion Criteria:

HbA1c greater than 75 mmol/mol (9.0%)
Child unwilling to agree to second insulin injection at a meal-time
Untreated coeliac disease or other concomitant condition likely to affect BG control
Food allergies (other than controlled Coeliac Disease)
Vegetarians, vegans or patients with religious dietary restrictions (as the standard meal contains meat)
Participant taking any glucose-containing medication concurrently
Intervention: Novolog mix 70/30
Trial phase: Phase 4
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 38
Group description: Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given one hour after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.

Insulin, Asp(B28)-: This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
Eligibility criteria:
Inclusion Criteria:

Diagnosis of Type 1 diabetes (for at least a year)
On multiple daily insulin injections, including basal long-acting insulin and rapid-acting insulin before each meal.
HbA1c < 75 mmol/mol (9.0%)
Participant and/or parent/legal guardian willing and able to give informed consent for participation in the study.
Family have a freezer in which to safely store the test meals.
In the Investigator's opinion, is able and willing to comply with all trial requirements.

Exclusion Criteria:

HbA1c greater than 75 mmol/mol (9.0%)
Child unwilling to agree to second insulin injection at a meal-time
Untreated coeliac disease or other concomitant condition likely to affect BG control
Food allergies (other than controlled Coeliac Disease)
Vegetarians, vegans or patients with religious dietary restrictions (as the standard meal contains meat)
Participant taking any glucose-containing medication concurrently
Intervention: Novolog mix 70/30
Trial phase: Phase 4
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 38
Group description: Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given two hours after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.

Insulin, Asp(B28)-: This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
Eligibility criteria:
Inclusion Criteria:

Diagnosis of Type 1 diabetes (for at least a year)
On multiple daily insulin injections, including basal long-acting insulin and rapid-acting insulin before each meal.
HbA1c < 75 mmol/mol (9.0%)
Participant and/or parent/legal guardian willing and able to give informed consent for participation in the study.
Family have a freezer in which to safely store the test meals.
In the Investigator's opinion, is able and willing to comply with all trial requirements.

Exclusion Criteria:

HbA1c greater than 75 mmol/mol (9.0%)
Child unwilling to agree to second insulin injection at a meal-time
Untreated coeliac disease or other concomitant condition likely to affect BG control
Food allergies (other than controlled Coeliac Disease)
Vegetarians, vegans or patients with religious dietary restrictions (as the standard meal contains meat)
Participant taking any glucose-containing medication concurrently
Intervention: Clascoterone
Trial phase: Phase 3
ATC code: D10AX06
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1(OC(=O)CC)C(=O)CO
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 317
Group description: Subjects in this arm received CB-03-01 (cortexolone 17α-propionate) Cream, 1% in the pivotal study and continued their CB-03-01 cream treatment in this open-label safety extension study. Subjects were instructed to apply CB-03-01 Cream, 1%, twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.

Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a

1% cream for the topical treatment of acne vulgaris.
Eligibility criteria:
Inclusion Criteria:

Participant has successfully completed participation in one of the Phase 3 pivotal studies [CB-03-01/25 and CB-03-01/26].
Participant agrees to use effective method of contraception throughout study, if applicable.
Participant has provided written informed consent or assent.
Participant is willing to comply with study instructions and return to the clinic for required visits.

Exclusion Criteria:

Participant is pregnant, lactating, or is planning to become pregnant during the study.
Participant has any skin disease or condition that could interfere with the safety evaluation of the test products or requires the use of interfering topical or systemic therapy.
Participant has any condition which, in the investigator's opinion, would make it unsafe or unsuitable for the participant to participate in this research study.
Participant plans to use any other investigational drug or device during participation in this study.
Participant has known hypersensitivity or previous allergic reaction to the drug or any of its ingredients.
Participant is or plans to use any restricted systemic and/or topical anti-acne preparations or medications during the study
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-Liposomal Bupivicaine will be administered at the end of the surgery. A new sustained-release local anesthetic solution (Bupivacaine Liposome Injectable Suspension) will be injected into the soft tissues around the join after surgery. Exparel is a novel-composition of bupivacine in which the drug is dissolved into liposomes which release it slowly over a period of 72 hours.

(Bupivacaine Liposome Injectable Suspension): Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
Eligibility criteria:
Inclusion Criteria:

Males and Females age 18+ years old having total knee arthroplasty at UCI
Meet at least one of the following criteria "opioid tolerant":
Taking 50mg oral morphine equivalent or more per day
On long-acting opioids (fentanyl pathc, oxycontin, methadone, etc.)
Being followed by a chronic pain physician
All subjects must be free of renal or hepatic dysfunction; defined as:
Glomerular filtration rate >60 mL/min/1.73m^2
AST & ALT <150, total bilirubin <1.0, INR <1.3 (if not taking anticoagulants)
No active hepatitis, no jaundice

Control group- received standard periarticular injection Research group- receives Exparel injection

Exclusion Criteria:

Allergy to local Anesthetic
Pregnancy
Nursing mothers
Children<18 years of age
Renal impairment (GFR<60 mL/min/1.73 m^2
Hepatic impairment (active hepatitis, elevated AST or ALT, jaundice)
Any history of ventricular arrhythmia or supraventricular tachycardia, or myocardial infarction within the last six months.
Intervention: Varenicline
Trial phase: Phase 2
ATC code: N07BA03 | S01XA28
SMILES: c1cnc2cc3c(cc2n1)C1CNCC3C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Open label trial of varenicline, administered as clinically indicated, for smoking cessation in patients prior to and after surgery.
Eligibility criteria:
Inclusion Criteria:

Smoker who has surgery scheduled 5-10 weeks in advance

Exclusion Criteria:

being contraindicated for varenicline use
evidence of psychiatric instability
being unwilling/unable to adhere to the study schedule
be unwilling to provide study access to medical records
being otherwise judged by the study team to be inappropriate for study participation
Intervention: Suvorexant
Trial phase: Phase 4
ATC code: N05CJ01 | N05CM19
SMILES: [H][C@@]1(C)CCN(c2nc3cc(Cl)ccc3o2)CCN1C(=O)c1cc(C)ccc1-n1nccn1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: 9 nights of 20 mg suvorexant

suvorexant: suvorexant 20 mg taken before sleep
Eligibility criteria:
Inclusion Criteria:

meet Diagnostic and Statistical Manual 5th ed criteria for insomnia
meet American College of Rheumatology criteria for fibromyalgia
otherwise good psychiatric and stable physical health

Exclusion Criteria:

other primary sleep disorders
pain symptoms unrelated to fibromyalgia
current pregnancy or breast-feeding
Intervention: Dasotraline
Trial phase: Phase 3
SMILES: N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 528
Group description: 4, 6, 8 mg flexibly dosed
Eligibility criteria:
Inclusion Criteria:

Completion of the treatment period of a dasotraline core study (ie, SEP360 221 or SEP360-321) for the treatment of BED.
Subject has agreed to participate by providing written informed consent and is willing and able to comply with the protocol, in the opinion of the investigator.
Subject has not taken any medication other than the study drug for the purpose of controlling BED symptoms during the core study.
Female subject must have a negative urine pregnancy test at open label (OL) Baseline; females who are post-menopausal (defined as at least 12 months of spontaneous amenorrhea) and those who have undergone hysterectomy or bilateral oophorectomy will be exempted from the pregnancy test.
Female subject of childbearing potential and male subject with female partner of childbearing potential must agree to use an effective and medically acceptable form of birth control (see Section 22, Appendix III) throughout the study period. Note: Continued use of an effective and medically acceptable form of birth control is recommended for 30 days after study completion.
Subject is judged by the investigator to be suitable for participation in a 12 month clinical trial involving open-label dasotraline treatment.
Subject can read well enough to understand the informed consent form and other subject materials.

Exclusion Criteria:

Subject is considered by the investigator to be at imminent risk of suicide, injury to self or to others, or damage to property.
Subject is considered a suicide risk in the investigator's opinion or has any previous history of suicide attempt within the past 12 months.
Subject answers "yes" to "suicidal ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C SSRS assessment at OL Baseline. Subjects who answer "yes" to this question must be referred to the Investigator for follow up evaluation.
Subject has a clinically significant abnormality including physical examination, vital signs, ECG, or laboratory tests that the investigator in consultation with the medical monitor considers to be inappropriate to allow participation in the study.
Subject has a positive urine drug screen (UDS) or breath alcohol test at OL Baseline.
Subject is breastfeeding.
Subject is at high risk of non-compliance in the investigator's opinion.
Intervention: Tranexamic acid
Trial phase: Phase 3
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 45
Group description: Patients in the intervention group were administered a 10mg/kg preoperative dose of tranexamic acid within 30 minutes prior to surgery followed by a 10mg/kg infusion over a 4hr period during surgery (for patients weighing over 100kg, a weight of 100kg was used for the dose calculation).
Eligibility criteria:
Inclusion Criteria:

All patients aged 18 or above undergoing acetabular ORIF.

Exclusion Criteria:

All patients aged below 18 years undergoing acetabulum surgery
Patients with color-blindness (color vision changes used to assess toxicity)
Patients with subarachnoid hemorrhage.
Patients with active intravascular coagulation.
Patients with a previous history of venous thromboembolism or with a history of hypercoaguable conditions (i.e. Factor V Leiden, antiphospholipid antibody).
Prisoners
Pregnant women
Intervention: Progesterone
Trial phase: Phase 4
ATC code: G03DA04 | G03FA04
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](C(C)=O)CC[C@@]21[H]
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Transdermal Nicotine Patch + Progesterone (200 mgs BID)

Progesterone (200 mgs BID): TNP + Progesterone
Eligibility criteria:
Inclusion Criteria:

Aged 18 - 45
Smoking at least 5 cigarettes/ day for at least one year
Regular menstrual cycles every 24-36 days for the previous 6 months
Motivated to quit smoking (i.e., a rating of at least "7 "on a 10-point scale where 1 is not at all motivated and 10 is extremely motivated)
In good health
Using an acceptable, non-hormonal birth control

Exclusion Criteria:

A history of major medical or psychological illnesses including:

liver disease
heart disease
diabetes
malignancy including history of breast cancer
deep vein thrombosis
blood coagulation problems including a history or family history of thrombophilia
liver failure
cervical intra-epithelial lesions III or greater that are untreated
other medical conditions that the physician investigators deems will make study participation unsafe for the subject
current or past history bipolar disorder or schizophrenia
current diagnosis of major depression
panic disorder or post-traumatic stress disorder
active drug (non-nicotine) and/or alcohol dependence
currently undergoing treatment with another pharmacological agent for smoking cessation
regular use of sedating medications including sleeping aids, antihistamines, and others use of nicotine from cigars, pipes, chewing tobacco
pregnant
breast- feeding or intending to become pregnant within 6 months
allergy to nicotine patch or progesterone
allergy to peanuts or other nuts.
Intervention: Gabapentin
Trial phase: Phase 4
ATC code: N02BF01 | N03AX12
SMILES: NCC1(CC(=O)O)CCCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 350
Group description: Subjects will receive gabapentin, 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week. Treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards.
Eligibility criteria:
Inclusion Criteria:

Adults scheduled for elective total knee or hip replacement
American Society of Anesthesiologists physical status 1-3
Participants must be able to read and write English

Exclusion Criteria:

Inability to complete questionnaires
Pregnancy
Litigation or workers compensation related to joint surgery
For 250 subjects in primary analysis - taking < 100 mg morphine equivalents/day. For 50 subjects to test gabapentin's effect on pupil diameter - taking >100 mg morphine equivalents/day
history of Raynaud's disease of the feet
suffering from a psychotic disorder or a recent psychiatric hospitalization
history of eye surgery or topical eye medications that would render pupillometry unreliable or would directly affect pupil diameter.
any disorder that would affect pupil responsivity or prevent accuracy of pupillometry such as movement disorders